Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PHIO PHARMACEUTICALS CORP.

(PHIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Phio Pharmaceuticals : HCW 23rd Annual Global Investment Conference Presentation

09/10/2021 EDT

DEVELOPING THE NEXT GENERATION

of immuno-oncology therapeutics

September 2021

w w w. phiopharma. com I Ticker: PHIO (NASDAQ)

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests" and similar expressions

are intended to identify forward-looking statements. These statements are based on Phio Pharmaceuticals Corp.'s (the "Company") current beliefs and expectations. Such statements include, but are not limited to, statements about the impact to our business and operations by the ongoing coronavirus pandemic, the development of our product candidates, the expected timing of certain developmental milestones (including timing or likelihood of regulatory filings and approvals), results from our preclinical and clinical studies, potential partnership opportunities, and the success of any such opportunities, the Company's competition and market opportunity and pro forma estimates. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual results may differ from those set forth in this presentation due to risks and uncertainties in the Company's business, including those identified under "Risk Factors" in the Company's most recently filed Annual Report on Form 10-K and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. The Company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

2

Immuno-oncology

Unmet Need

Immuno-oncology: Definition and key unmet needs

Immuno-oncology is the science of harnessing a patient's immune system to better

recognize and attack cancer cells, through:

Unmet need

Cell therapy

e.g. CAR-T adoptive cell therapy (ACT)

  • Limited activity in solid tumors
  • Cost

Unmet need

Systemic immune stimulating therapy

e.g. checkpoint inhibitors

  • High rate of non-responders & relapse
  • Immune related adverse events

Solutions include:

"Reprogramming" cells for ACT

"Reprogramming" tumor microenvironment

- Activate the otherwise dysfunctional immune

- Remove the barriers of the tumor immune

cells

microenvironment

4

Various adoptive cell therapies share similar issues

Adoptive

Cell

Therapy

  1. cells
    NK cells

Tumor Infiltrating Lymphocytes

TCR-T cells

CAR-T cells

Stimulated NK cells

CAR-NK cells

Regardless of source / lineage, manufacturing manipulations often lead to dysfunctional features including:

Terminal differentiation

Senescence

Exhaustion

Suboptimal metabolism

"Dysfunctional features induced during laboratory-based manipulations of immune products prior to adoptive

cell transfer has a determining effect on outcomes"

Alter cell phenotype:

Combination therapies

-

Checkpoints & co-inhibitory signals

- Immunomodulation

-

Metabolic programing

-

Immune cells

-

Epigenetic programing

-

Tumor cells

During manufacturing

After manufacturing

5

Disclaimer

Phio Pharmaceuticals Corp. published this content on 10 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 September 2021 11:11:11 UTC.


ę Publicnow 2021
All news about PHIO PHARMACEUTICALS CORP.
10/18PHIO PHARMACEUTICALS : Announces Upcoming Presentation at the SITC 36th Annual Meeting
PR
10/07PHIO PHARMACEUTICALS : Presents New BRD4 Data at the AACR-NCI-EORTC International Conferen..
PR
09/30PHIO PHARMACEUTICALS : Announces Two Upcoming Data Presentations at Scientific Conferences..
PR
09/16US Stocks Mostly Lower Thursday After Surprise Retail Sales Gain, Rise in Jobless Claim..
MT
09/16US Stocks End Mostly Lower as Investors Weigh Surprise Retail Sales Gain Against Rising..
MT
09/16Health Care Stocks Largely Sitting Out Markets Recovery This Afternoon
MT
09/16Health Care Stocks Muted in Premarket Thursday
MT
09/16PHIO PHARMACEUTICALS : Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immu..
PR
09/16Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Imm..
CI
09/10PHIO PHARMACEUTICALS : HCW 23rd Annual Global Investment Conference Presentation
PU
More news
Analyst Recommendations on PHIO PHARMACEUTICALS CORP.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -14,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,47x
Yield 2021 -
Capitalization 21,9 M 21,9 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 0,44x
Nbr of Employees 10
Free-Float 99,7%
Chart PHIO PHARMACEUTICALS CORP.
Duration : Period :
Phio Pharmaceuticals Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHIO PHARMACEUTICALS CORP.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,62 $
Average target price 6,00 $
Spread / Average Target 270%
EPS Revisions
Managers and Directors
Gerrit Dispersyn President, Chief Executive Officer & Director
Caitlin Kontulis Secretary, VP-Finance & Administration
Robert J. Bitterman Chairman
Simon Fricker Vice President-Research
James Cardia Vice President-Business Operations
Sector and Competitors
1st jan.Capi. (M$)
PHIO PHARMACEUTICALS CORP.-39.78%22
MODERNA, INC.226.29%137 595
LONZA GROUP AG32.74%61 065
IQVIA HOLDINGS INC.41.93%48 579
SEAGEN INC.-0.30%31 768
CELLTRION, INC.-39.00%25 528